Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium

European Journal of Pharmacology

Volumn 306, Issue 1-3, 1996, Pages 181-186

  Koutsilieri, Eleni ^a   Chen, Tzyh Shi ^b   Rausch, Wolf Dieter ^b   Riederer, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

astrocyte; MPP+ (1 methyl 4 phenylpyridinium); neuronal culture; selegiline

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; NEUROTOXIN; RADIOISOTOPE; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; EMBRYO; IMMUNOCYTOCHEMISTRY; MESENCEPHALON; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030582079     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00184-7     Document Type: Article

References (33)

1. Amenta, F., S. Bograni, S. Cadel, F. Ferrante, B. Valsecchi and J.A. Vega, 1994. Microanatomical changes in the frontal cortex of aged rats: effect of L-deprenyl treatment, Brain Res. Bull. 34, 125.
2. Banker, G.A., 1980, Trophic interactions between astroglial cells and hippocampal neurons in culture, Science 209, 809.
3. Biagini, G., M. Zoli, K. Fuxe and L.F. Agnati, 1993, L-Deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain, NeuroReport 4, 955.
4. R treatment in Parkinson's disease: a long term study, J. Neural Transm. 64, 113.
5. Bottenstein J.E. and G.H. Sato, 1979, Growth of a rat neuroblastoma cell line in serum-free supplemented medium Proc. Natl. Acad. Sci. USA 76, 514.
6. Gerlach, M., P. Riederer and M.B.H. Youdim, 1992, The molecular pharmacology of L-deprenyl, Eur. J. Pharmacol. Mol. Pharmacol. Sect. 226, 97.
7. Heikkila, R.E., L. Manzino, F.S. Cabbat and R.S. Duvoisin, 1984, Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors, Nature 311, 467.
8. Kalderon, N., A.A. Alfieri and Z. Fuks, 1990, Beneficial effects of x-irradiation on recovery of lesioned mammalian central nervous tissue, Proc. Natl. Acad. Sci. USA 87, 10058.
9. Knoll, J., 1978, The possible mechanisms of action of (-)-deprenyl in Parkinsóns disease, J. Neural Transm. 43, 177.
10. Knoll, J., Z. Ecsery, K. Kelemen, J. Nievel and B. Knoll, 1965, Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer, Arch. Int. Pharmacodyn. Ther. 155, 154.
11. +), J. Neural Transm. (Gen. Sect.) 94, 189.
12. +-treated dopaminergic neurons, Eur. J. Pharmacol. Mol. Pharmacol. Sect. 269, R3.
13. Li, X.-M., J. Qi, A.V. Juorio and A.A. Boulton, 1993, Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-deprenyl and other monoamine oxidase B inhibitors in C6 glioma cells, J. Neurochem. 61, 1573.
14. Lindvall, O. and A. Björklund, 1983, Dopamine and norepinephrine containing neuron systems: their anatomy in the rat brain, in: Chemical Neuroanatomy, ed. P.C. Emson (Raven Press, New York) p. 229.
15. Mytilineou, C. and G. Cohen, 1985, Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion, J. Neurochem. 45, 1951.
16. Nieto-Sampedro, M., M. Manthorpe, G. Barbin, S. Varon and C. W. Cotman, 1983, Injury-induced neuronoirophic activity in adult rat brain: correlation with survival of delayed implants in the wound cavity, J. Neurosci. 3, 2219.
17. O'Malley, E.K., B.-A. Sieber, I.B. Black and C.F. Dreyfus, 1992, Mesencephalic type I astrocytes mediate the survival of substantia nigra dopaminergic neurons in culture. Brain Res, 582, 65.
18. Otto, D. and K. Unsicker, 1990, FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice, J. Neurosci. 10, 1912.
19. +-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF, Brain Res. 599, 83.
20. Reynolds, G.P., J.D. Elsworth, K. Blau, M. Sandler, A.J. Lees and G. M. Stern, 1978. Deprenyl is metabolized to methamphetamine and amphetamine in man, Br. J. Clin. Pharmacol. 6, 542.
21. Riederer, P. and M.B.H. Yudim, 1986, Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl, J. Neurochem. 46, 1359.
22. Romijn, H.J., A.M.M.C. Habets, M.T. Mud, P.S. Wolters, 1982, Nerve outgrowth, synaptogenesis and bioelectric activity in fetal rat cerebral cortex tissue cultured in serum-free, chemically defined medium, Dev. Brain Res. 2, 583.
23. Roy, E. and P.J. Bedard, 1993, Deprenyl increases survival of rat foetal nigral neurons in culture, NeuroReport 4, 1183.
24. Schambra, U.B., J.M. Lauder and J. Silver, 1992, Atlas of the Prenatal Mouse Brain (Academic Press, San Diego) p. 76.
25. Schinelli, S., A. Zuddas, I.J. Kopin, J.L. Barker and U. Di Porzio, 1988, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism and 1-methyl-4-phenylpyridinium uptake in dissociated cell cultures from the embryonic mesencephalon, J. Neurochem. 50, 1900.
26. Seniuk, N.A., J.T. Henderson, W.G. Tatton and J. C. Roder, 1994, Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J. Neurosci. Res, 37, 278.
27. Skibo, G., L. Ahmed, P. Yu, A.A. Boulton and S. Fedoroff, 1993, L-Deprenyi, A-monoamine oxidase-B (MAO-B) inhibitor acts on the astroglia cell cycle at the G1/G0 boundary, Proc. Am. Soc. Cell Biol. (Abstr.) 12, 532.
28. Sofic, E., 1986, Untersuchung von biogenen Aminen, Metaboliten, Ascorbinsäure und Glutathion mittels HPLC-ECD und deren Verhalten in ausgewählten Lebensmitteln und im Organismus von Tier und Mensch. Dissertation, Technische Universität Wien.
29. Sziraki, I., V. Kardos, M. Patthy, M. Patfalusi, J. Gaal, M. Solti, E. Kollar and J. Singer, 1994, Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2′-methyl-MPTP *, J. Neural Transm. (Suppl.) 41, 207.
30. Tatton, W.G., 1993, Selegiline can mediate neuronal rescue rather than neuronal protection, Movem. Disorders 8, 20.
31. Tetrud, J. and W. Langsten, 1989, The effect of deprenyl (Selegiline) on the natural history of Parkinsons disease, Science 245, 519.
32. Vizuete, M.L., V. Steffen, A. Ayala, J. Cano and A. Machado, 1993, Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum, Neurosci. Lett. 152, 113.
33. + in vivo, Eur, J. Pharmacol. 243, 241.